Home / Pharmaceuticals / Nosocomial Infection Treatment Market By Infection (Ventilator Associated Pneumonia, Urinary Tract Infection, Blood Stream Infection, Surgical Site Infection, Gastrointestinal Infection, MRSA), By Treatment (Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2024

Nosocomial Infection Treatment Market By Infection (Ventilator Associated Pneumonia, Urinary Tract Infection, Blood Stream Infection, Surgical Site Infection, Gastrointestinal Infection, MRSA), By Treatment (Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2024

Published: Feb 2017 | Report Code: 58358-02-17

According to the WHO, nosocomial infection is defined as “an infection acquired in hospital by a patient who was admitted for a reason other than that infection”. An infection occurring in a patient in a hospital or other health care facility in whom the infection was not present or incubating at the time of admission. This includes infections acquired in the hospital but appearing after discharge, and also occupational infections among staff of the facility. The infection is caused due to bacteria, viruses, fungi and parasites. All hospital patients are susceptible to contract infection especially pediatric and geriatric section and immune compromised patient, due to extended stay in hospital, usage of indwelling catheters, some failure of health care provider or over dosage of antibiotics. The global nosocomial infection treatment market is anticipated to progress during the forecast period due to rising prevalence of nosocomial infections, increase in number of surgical procedures, and escalating focus on disinfection and sterilization technology.

The report titled “Global Nosocomial Infection Treatment Market - Growth, Share, Opportunities and Competitive Analysis, 2016–2024” offers strategic insights into the overall nosocomial infection treatment market along with the market size and estimates for the duration 2014 to 2024. The study covers in-depth analysis of multiple market segments based on type of product and different geographies. The infection types studied for analyzing the overall nosocomial infection treatment market is majorly segmented into ventilator associated pneumonia, urinary tract infection, blood stream infection, surgical site infection, MRSA and others. The treatment types considered for analyzing the market are antibacterial, antifungal, antiviral treatments and others.

Geographically, the Global Nosocomial Infection Treatment market is studied for the following regional markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Mexico
    • Brazil
    • Rest of LATAM
  • Middle East and Africa

Market size and forecast for these regional and country level markets are presented in this study for the period 2014-2024. Market growth rates for the forecast period 2016-2024 are also included in this report, considering 2015 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global nosocomial infection treatment market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global nosocomial infection treatment market. This report concludes with company profiles section that highlights major information about the key players engaged in global nosocomial infection treatment market. In-depth competitive environment analysis and historical years market size data are also provided in the report.

Nosocomial Infection Treatment Market

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Nosocomial Infection Treatment Portraiture
2.2 Global Nosocomial Infection Treatment Share, by Infection Type, 2015 (US$ Mn)
2.3 Global Nosocomial Infection Treatment, by Treatment Type, 2015 (US$ Mn)
2.4 Global Nosocomial Infection Treatment, by Geography, 2015 (Value %)

Chapter 3 Global Nosocomial Infection Treatment Analysis
3.1 Global Nosocomial Infection Treatment Overview
3.2 Epidemiology of Nosocomial Infections
3.3 Guidelines for Nosocomial Infection Control
3.4 Market Dynamics
3.4.1 Market Drivers
3.4.2 Challenges
3.4.3 Opportunities
3.5 Attractive Investment Proposition, 2015
3.6 Market Positioning Analysis of Key Players: Nosocomial Infection Treatment Market, 2015

Chapter 4 Global Nosocomial Infection Treatment Analysis, by Infection Type, 2014-2024 (US$)
4.1 Introduction
4.2 Ventilator Associated Pneumonia
4.3 Urinary Tract Infection
4.4 Blood Stream Infection
4.5 Surgical Site Infection
4.6 Gastrointestinal Infection
4.7 MRSA
4.8 Others (ENT Infections, Skin Infection, and Bone Infection)

Chapter 5 Nosocomial Infection Treatment Analysis, by Treatment Type, 2014-2024 (US$)
5.1 Introduction
5.2 Antibacterial Treatment
5.3 Antiviral Treatment
5.4 Antifungal Treatment
5.5 Others

Chapter 6 Global Nosocomial Infection Treatment, by Geography
6.1 Preface
6.2 North America (U.S. & Canada)
6.3 Europe (U.K., Germany & Rest of Europe)
6.4 Asia Pacific (China, Japan, and Rest of APAC)
6.5 Latin America (Brazil, Mexico and Rest of LATAM)
6.6 Middle East and Africa

Chapter 7 Company Profiles
7.1 Abbott
7.2 Bayer
7.3 Becton, Dickinson and Company
7.4 Belimed
7.5 BioMerieux
7.6 Cantel
7.7 Cepheid
7.8 Getinge Group
7.9 Kimberly-Clark Corp.
7.10 Merck & Co
7.11 Nordion
7.12 Pfizer
7.13 Roche
7.14 Sakura Seiki
7.15 BioMérieux
7.16 Steris
7.17 Johnson & Johnson
7.18 Sterigenics International, Inc.
7.19 Halyard Health, Inc.
7.20 Advanced Sterilization Products
7.21 Matachana Group
7.22 Other Notable Players

Note:

  • Profiles of specific players, if required, shall be added to the report upon request

List of Tables :

TABLE 1 Global Nosocomial Infection Treatment, By Infection Type 2014-2024 (US$ Mn)
TABLE 2 Nosocomial Infection Treatment, by Treatment Type , 2014-2024 (US$ Mn)
TABLE 3 Global Nosocomial Infection Treatment, by Geography, 2014 – 2024 (US$ Mn)
TABLE 4 North America Nosocomial Infection Treatment, by Country, 2014 – 2024 (US$ Mn)
TABLE 5 Europe Nosocomial Infection Treatment, by Country, 2014 – 2024 (US$ Mn)
TABLE 6 Asia-Pacific Nosocomial Infection Treatment, by Country, 2014 – 2024 (US$ Mn)
TABLE 7 Latin America Nosocomial Infection Treatment, by Country, 2014 – 2024 (US$ Mn)
TABLE 8 Middle East and Africa Nosocomial Infection Treatment, by Country, 2014 – 2024 (US$ Mn)
TABLE 9 Abbott, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 10 Bayer, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 11 Becton, Dickenson and Company: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 12 Belimed: Company Snapshot (Business Description; Financial Performance; Product Position Portfolio; News Coverage)
TABLE 13 BioMerieux: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 14 Cantel: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 15 Cepheid: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 16 Gettinge Group: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 17 Kimberly- Clark Corp.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 18 U Merck & Co: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 19 Nordion: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 20 Pfizer: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 21 Roche: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 22 Sakura Seiki: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 23 BioMérieux: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 24 Steris: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 25 Johnson & Johnson: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 26 Sterigenics International, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 27 Halyard Health, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 28 Advanced Sterilization Products: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 29 Matachana Group: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)

List of Figures :

FIG. 1 Global Nosocomial Infection Treatment: Research Methodology
FIG. 2 Global Nosocomial Infection Treatment Share, by Infection, 2015 (US$ Mn)
FIG. 3 Global Nosocomial Infection Treatment, by Application Type, 2015 (US$ Mn)
FIG. 4 Global Nosocomial Infection Treatment, by Geography, 2015 (Value %)
FIG. 5 Attractive Investment Proposition: Global Nosocomial Infection Treatment, by Geography
FIG. 6 Competitive Analysis: Key Players in Global Nosocomial Infection Treatment
FIG. 7 Global Ventilator Associated Pneumonia Market, 2014 – 2024 (US$ Mn)
FIG. 8 Global Urinary Tract Infection Market, 2014 – 2024 (US$ Mn)
FIG. 9 Global Blood Stream Infection Market, 2014 – 2024 (US$ Mn)
FIG. 10 Global Surgical Site Infection Market, 2014 – 2024 (US$ Mn)
FIG. 11 Global Gastrointestinal Infection Market, 2014 – 2024 (US$ Mn)
FIG. 12 Global MRSA Market, 2014 – 2024 (US$ Mn)
FIG. 13 Global Others (ENT Infections, Skin Infection, and Bone Infection) Market, 2014 – 2024 (US$ Mn)
FIG. 14 Global Antibacterial Treatment Market , 2014 – 2024 (US$ Mn)
FIG. 15 Global Antiviral Treatment Market, 2014 – 2024 (US$ Mn)
FIG. 16 Global Antifungal Treatment Market, 2014 – 2024 (US$ Mn)
FIG. 17 Global Other Treatment Market, 2014 – 2024 (US$ Mn)

Based on the type of Infection, the global nosocomial infection treatment market is segmented as follows:

  • Ventilator Associated Pneumonia
  • Urinary Tract Infection
  • Blood Stream Infection
  • Surgical Site Infection
  • Gastrointestinal Infection
  • MRSA
  • Others (ENT Infections, Skin Infection, and Bone Infection)

Pneumonia and surgical site infection are the most common hospital acquired infections occupying the largest market share. Nosocomial pneumonia is observed in several varied groups. The patient on ventilators in ICU are more prone to infection, the rate of infection caused by pneumonia is 3% per day and associated with high fatality rate. Surgical site infection is the next followed up market, with incidence rate varying from 0.5% to 15% depending on type of operation and patient status. Bloodstream infection occupies almost 15% to 20% of nosocomial infections, affecting almost 1% of all hospitalized patients. It is associated with increased mortality rate and extended stay in an intensive care unit and hospital, therefore surveillance and prevention of BSI are high priorities. Urinary tract infection occurs due to usage of bladder catheter and associated with less morbidity compared to other nosocomial infection. MRSA is the second most common cause of HAIs reported to the NHSN. The CDC also estimates that 49% to 65% hospital acquired S. aureus infections reported to the NHSN are caused by methicillin resistant strains.

Nosocomial Infection Treatment Market

Based on the type of treatment, the global nosocomial infection treatment market is segmented as follows:

  • Antibacterial Treatment
  • Antiviral Treatment
  • Antifungal Treatment
  • Others

Antibiotic therapy is empirical in intensive care unit, due risk of emergence of emergency situations, infection severity in neutropenia, and large presence immunosuppressed and elderly patient. The selection of antibiotic therapy depends upon most common bacterial species causing infection, the pattern of the antibiotic resistance in particular hospital, patient clinical status and previous therapy. It covers both gram positive and gram negative bacteria. Initial antibiotic therapy includes ceftazimide plus vancomycin; if vancomycin is not used, mono-therapy with ceftazidime, imipenem, cefepime or meropenem is given. Multiple antibiotics are used when the organism develops resistant mutant, patient is immunocompromised, the higher serum activity is required, or blood culture consistently shows positive bacteria even after single therapy. The conventionally long used initial regimen of combination therapy recommended includes antipseudomonal penicillin plus aminoglycoside or an antipseudomonal cephalosporin (ceftazidime) plus an aminoglycoside. Antifungal drugs are used to treat fungal infection include amphotericin B, nystatin, ketoconazole, itraconazole, and fluconazole. Antiviral drugs used are Acyclovir, ganciclovir, foscarnet, and amantadine, which inhibit the growth or multiplication of the virus. Empiric antibiotic, antiviral and antifungal used to treat infection, avoid any further complication including organ damage.

Nosocomial Infection Treatment Market

Geographically, the global nosocomial infection treatment market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Nosocomial Infection Treatment Market

North America currently dominates the regional global nosocomial infection market followed by Europe. The key drivers for North America market are rising prevalence of nosocomial infection, multi-drug resistant microbes, and rising demand for advanced therapeutics. The U.S is the major market in North America due to incessant technological advancements in surgical procedures, sterilization equipment and state of art health care facilities. Europe is the second largest market attributed to rise in geriatric population which is prone to nosocomial infection, government initiative to improve the healthcare facility and advancement in antimicrobial therapeutics. Asia Pacific is the fastest growing market due to factors such as increasing investment in health care facilities, rise in per capita income fueled with economic development, huge government investments in development of healthcare infrastructure, rising public awareness coupled with high prevalence of nosocomial infection.

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients